RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination to find the safest dose and…
Matched conditions: RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo may bridge more patients to lifesaving CAR-T therapy
Disease control Recruiting nowThis study tests whether giving two drugs—golcadomide and rituximab—before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to keep the disease in check so more patients can qualify for and rec…
Matched conditions: RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug may boost CAR-T success in tough lymphomas
Disease control Recruiting nowThis study tests a drug called odronextamab given before CAR-T cell therapy for people with large B-cell lymphoma that has returned or not responded to treatment. The goal is to see if this approach can keep the cancer under control and help more patients successfully receive CAR…
Matched conditions: RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug combo aims to outsmart tough lymphoma
Disease control Recruiting nowThis study is for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It tests a combination of two drugs: epcoritamab, which helps the immune system attack cancer cells, and ibrutinib, which blocks signals that help cance…
Matched conditions: RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug combo aims to boost stem cell transplant success in hard-to-treat lymphoma
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatment. About 43 adults will receive the combination before an autologous stem …
Matched conditions: RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 15:59 UTC